Monoclonal antibody
Monoclonal antibody is a pharmaceutical drug with 8 clinical trials. Currently 5 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
100.0%
2 of 2 finished
0.0%
0 ended early
5
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
COVID-19 International Drug Pregnancy Registry
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Immunotherapy in Lymphoma
Clinical Trials (8)
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
COVID-19 International Drug Pregnancy Registry
Impact of In Utero Exposure to Immunomodulatory Drugs on Neonatal Immune System Development
Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies
Immunotherapy in Lymphoma
Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8